Highlights

  • Audeara reported group revenue of A$656,747 for the September quarter, 37.7 per cent higher than the June quarter.
  • Closing cash fell to A$247,000 from A$740,000, and the Appendix 4C estimates 0.19 quarters of funding at current spending.
  • A second placement tranche of about A$505,000 needs shareholder approval at the annual general meeting on 24 November 2026.
  • Two AI noise-reduction licensing programs entered commercial production, with initial purchase orders of roughly A$31,000.

A$656,747. That is what Audeara (ASX:AUA) booked in group revenue for the quarter ended 30 September 2026, but the cash tells a tighter story. The Australian audio and hearing technology company ended the period with A$247,000, down from A$740,000, and it now leans on a placement tranche that shareholders have yet to approve.

Revenue and receipts

Audeara said revenue was 37.7 per cent higher than in the June quarter. Australian wholesale contributed A$525,390, while AUA Technology contributed A$62,195, growth of 193.2 per cent on the previous quarter.

Customer receipts, however, were A$617,000, down 13.0 per cent from June. The company attributed the fall to delayed purchase orders from AUA Technology customers. The gap between revenue and receipts suggests some of the quarter's revenue had not yet been collected as cash, although the report does not break the difference down. Revenue growth and receipts moved in opposite directions.

Cash and funding

Net operating cash outflow was A$1.292 million, compared with A$795,000 in the June quarter. Audeara said the increase mainly reflected inventory built ahead of expected AUA Technology orders. If those orders arrive, the stock could convert into sales. If they are delayed again, the cash tied up in inventory would stay on the balance sheet for longer. No dates were given for the expected orders.

The Appendix 4C estimated 0.19 quarters of funding at the current rate of spending. The company has a research and development rebate loan facility of A$1.107 million, repayable by 31 December 2026, or earlier if the rebate is received.

Audeara is raising A$1.26 million through a two-tranche placement priced at A$0.033 per share. The first tranche raised A$755,000 before costs and was issued on 28 August 2026. The second, of about A$505,000, is subject to shareholder approval at the annual general meeting on 24 November 2026, so it is proposed rather than received.

Product and partner developments

Two AI noise-reduction licensing programs entered commercial production, with initial purchase orders of roughly A$31,000. These are initial orders rather than recognised revenue, and the report offers no forecast for further volumes.

Clinico launched in Taiwan after the end of the quarter, following fulfilment of introductory Auracast orders of about A$164,000. The company said donated systems are not incremental Audeara sales, and a figure of A$734,000 cited in the report is a historical total rather than new revenue.

Audeara began the process for a US OTCID quotation on 14 September 2026. Approval depends on review and acceptance by OTC Markets, so the outcome is not assured. The company also attended the EUHA 2026 hearing industry congress in Hanover, Germany, in October.

Priorities ahead

Audeara's stated aim is to convert production milestones and established partner programs into further orders, revenue and cash receipts. Its listed priorities are production orders for the licensing programs, wholesale and partner orders involving ShokzHear, Bolton Clarke and Clinico, progress on the OTCID application, and approval of the second placement tranche.

With a funding estimate of 0.19 quarters and the loan repayment date at the end of December 2026, the timing of tranche approval, the rebate and the conversion of orders into cash will matter. The report provides no revenue guidance, and its statements about future orders are intentions rather than contracted revenue.